|
See related Alkeran information |
|
|
|
Manufacturer |
Aspen Pharmacare |
|
Distributor |
Hong Kong: Primal |
|
Contents |
Melphalan |
|
Indications |
Listed in Dosage. |
|
Dosage |
Tab Multiple myeloma 0.15 mg/kg body wt/day in divided doses for 4 days repeated at intervals of 6 wk. Advanced ovarian adenocarcinoma 0.2 mg/kg body wt/day for 5 days. Repeated 4-8 wkly or as soon as peripheral blood count has recovered. Breast carcinoma 0.15 mg/kg body wt daily or 6 mg/m2 BSA/day for 5 days & repeated 6 wkly. Polycythaemia rubra vera Remission induction: 6-10 mg daily for 5-7 days, then 2-4 mg daily until satisfactory disease control achieved. Maintenance: 2-6 mg once/wk. Inj Multiple myeloma 0.4 mg/kg body wt repeated at appropriate intervals. Ovarian adenocarcinoma 1 mg/kg body wt given at 4 wk intervals. Malignant melanoma Upper extremity perfusion: 0.6-1 mg/kg body wt. Lower extremity perfusion: 0.8-1.5 mg/kg body wt. Soft tissue sarcoma Upper extremity perfusion: 0.6-1 mg/kg body wt. Lower extremity perfusion: 1-1.4 mg/kg body wt. Advanced neuroblastoma 100-240 mg/m2 BSA. |
|
Administration |
Should be taken on an empty stomach (Take on an empty stomach 1 hr before or 2 hr after meals. Swallow whole, do not break/crush.). |
|
Contraindications |
Pregnancy (1st trimester) & lactation. |
|
Special Precautions |
Immunisation using a live organism vaccine has the potential to cause infection in immunocompromised host. Monitor blood counts; should not be given to patients who have recently undergone radio- or chemotherapy. Renal impairment. Ensure adequate contraceptive precautions. |
|
Adverse Drug Reactions |
Bone marrow depression, thrombocytopenia, anaemia; nausea, vomiting, diarrhea; stomatitis, alopecia, elevated blood urea; muscle atrophy & fibrosis, myalgia, increased blood creatinine phosphokinase, compartment syndrome; subjective & transient sensation of warmth &/or tingling.
View ADR Monitoring Form |
|
Drug Interactions |
Live organism vaccines, nalidixic acid, cyclosporin.
View more drug interactions with Alkeran |
|
Pregnancy Category (US FDA) |
Category D: There is positive evidence of human foetal risk, but the benefits from use in pregnant women may be acceptable despite the risk (e.g., if the drug is needed in a life-threatening situation or for a serious disease for which safer drugs cannot be used or are ineffective). |
|
ATC Classification |
L01AA03 - melphalan ; Belongs to the class of alkylating agents, nitrogen mustard analogues. Used in the treatment of cancer. |
|
Presentation/Packing |
|
Form |
Packing |
Photo |
|
Alkeran film-coated tablet |
|
|
Alkeran injection |
|
|
|
Manufacturer: |
Aspen Pharmacare |
|
Distributor: |
Hong Kong: Primal
|
|
|
|
